A few days ago, Minkang Medical Technology (Tianjin) Co., Ltd. (Minkang Bio) held a meeting in Lu’an, Anhui to disclose the company’s major financing information and successfully held the opening ceremony of the new production base in Lu’an. Minkang Biotechnology Chairman Gan Jianmin gave an important keynote speech. Well-known media such as Phoenix.com, Yiou.com, Zhongan Online and Lu'an TV followed up and reported the whole process.
Minkang Biotechnology is a national high-tech enterprise that concentrate on using biosensors technology to R&D, production and sale products for detecting chronic disease. It was registered and established in Beijing on June 8, 2010, and moved to Tianjin Binhai New Area in September, 2013. MinKang Biotechnology Tianjin modern production base has a world-class 2000 square meters 100000 GMP purification workshop, 200 square meters laboratory and 1000 square meters professional R&D center. Series of blood glucose meters and matched test strips with the characteristics of “ Accurate Simple Economy” are recognized by the mass consumers. It has more than 65000 terminals and 200 channels in China. Products contain detection of blood glucose, blood lipid, HbA1c, blood ketone, uric acid and multinomial diabetic index.
During the epidemic situation, Minkang Biotechnology not only hard boosted to resume work and production to meet the daily testing needs of the majority of diabetic patients, but also actively participated in the production of novel coronavirus protective equipment and its medical surgical masks were exported to overseas regions such as Germany. Under the downward pressure of the economy, Minkang Biotechnology is pragmatic and stable and focusing on its own field, always ensuring the normal progress of new product plans. And successfully publishing four new blood glucose meters and blood lipid meters during the conference.
Depending on a professional scientific research team and strong technical capabilities, Minkang Biotechnology has established a good reputation in the industry for many years and is also favored by many well-known investment institutions. During the meeting, Minkang Biotechnology announced that it has received 100 million investment from institutions such as China Venture Capital Co., Ltd. and Anhui High-tech Industry Investment Co., Ltd. The company will continue to increase the scientific research investment of the Tianjin headquarters, accelerate the construction of a new 92.8 acres production base in Lu'an, expand production capacity and scale of production. Base itself in Tianjin and radiate the whole country.
At this conference, Chairman Zhu Yaoyi from the In Vitro Diagnostic Branch of the China Medical Device Industry Association and Dr. Fang Zhaohui from the Diabetes Professional Committee of the Chinese Society of Traditional Chinese Medicine delivered wonderful academic speeches to the guests from their respective fields and affirming the focus of Minkang Biotechnology strategic conception of the development of diabetes monitoring services to the comprehensive management of chronic diseases. Minkang Biotechnology will take advantage of the rapid growth of our country's internet medical services, depending on Tianjin's industrial advantages in big data, artificial intelligence and other fields to build the entire chronic disease management ecosystem. Beginning with diabetes monitoring, collect and analyze relevant data, gradually develop cooperation with medical resources, open up the integration of offline and online diagnosis and treatment, and explore a long-term development model from single diabetes detection to full chronic disease management. Through Internet medical care --- the "contact-less" medical services brought by online communication and inquiries to clinics can relieve the pressure of medical treatment in offline hospitals, and can also meet the home treatment and medication needs of chronic and mild patients.
